Xenetic Biosciences, Inc. Reports Full Year 2025 Financial Results

Xenetic Biosciences (NASDAQ:XBIO) reported full-year 2025 results and scientific progress on its DNase I immuno-oncology program.

Rhea-AI Summary

Xenetic Biosciences (NASDAQ:XBIO) reported full-year 2025 results and scientific progress on its DNase I immuno-oncology program. Key points: net loss of $2.7 million, royalty revenue up ~19% to $3.0 million, and year-end cash of $7.9 million. The company advanced preclinical, translational and IND-enabling activities and supported investigator-initiated trials in PDAC and proposed LBCL/CAR-T combinations.

Positive

• Royalty revenue +19% to $3.0 million in 2025
• Year-end cash $7.9 million, up ~$1.7 million year-over-year
• Progress toward IND-enabling activities for DNase I

Negative

• Reported net loss $2.7 million for 2025
• Research and development spend reflects increased DNase process costs

Argus Mar 13 session

+9.46% close to close Open Argus

Details

News Market Reaction – XBIO

On Mar 13, the day this news came out, XBIO closed 9.46% above the previous close.

Data tracked by StockTitan Argus for the Mar 13 session.

Market Context

On Mar 13, the day this news came out, the stock closed 9.5% above the previous close. A strong posi...

Analysis

On Mar 13, the day this news came out, the stock closed 9.5% above the previous close. A strong positive reaction aligns with the company’s continued progress in DNase-based oncology and improving financial profile, including FY2025 royalty revenue of $3.0M and year-end cash of $7.9M. Historically, earnings moves averaged -0.66%, so a large upside move would stand out from past patterns. Investors would still need to weigh financing dependence and execution on IND-enabling work when considering how durable such strength might be.

Key Figures

Net loss: ~$2.7M Royalty revenue: $3.0M R&D expenses: $3.1M +5 more

Net loss

~$2.7M

Year ended Dec 31, 2025

Royalty revenue

$3.0M

FY2025 Takeda sublicense, up ~19% from $2.5M in 2024

R&D expenses

$3.1M

FY2025, down from $3.3M in prior year

G&A expenses

$2.7M

FY2025, down ~20% vs prior year

Year-end cash

$7.9M

Cash balance at Dec 31, 2025

Cash increase

~$1.7M

Change in cash vs prior year-end

Underwritten offering proceeds

~$4.0M

Net proceeds from Oct 2025 underwritten public offering

Impairment charge

$0.7M

R&D impairment in 2024 that did not recur in 2025

Previous Earnings Reports

5 past events · Latest: Nov 13

Same Type 5 events

1. Nov 13

   Q3 2025 earnings

   24h Move

   -2.6%

   Q3 2025 results with higher revenue, larger R&D spend and added cash runway.

2. Aug 13

   Q2 2025 earnings

   24h Move

   +7.2%

   Q2 2025 results showing lower expenses, net loss of $0.7M and $4.8M cash.

3. May 14

   Q1 2025 earnings

   24h Move

   +2.0%

   Q1 2025 results with revenue up 16.1%, lower operating expenses and $5.2M cash.

4. Mar 19

   FY 2024 earnings

   24h Move

   +1.9%

   Full-year 2024 results with $4.0M net loss, $2.5M royalties and $6.2M cash.

5. Nov 13

   Q3 2024 earnings

   24h Move

   -11.6%

   Q3 2024 results showing lower R&D spend and ongoing DNase program progress.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

neutrophil extracellular traps, deoxyribonuclease, dnase i, pancreatic ductal adenocarcinoma, +4 more

8 terms

neutrophil extracellular traps medical

"evidence supporting neutrophil extracellular traps (NETs) as drivers of cancer progression"

Neutrophil extracellular traps (NETs) are web-like strands of DNA and proteins expelled by certain white blood cells to trap and neutralize invading germs, like a spider spinning a sticky web to catch insects. For investors, NETs matter because they are linked to inflammation, blood clots and chronic disease, making them potential targets for new diagnostics and therapies and a factor in safety and efficacy assessments for drug and device development.

deoxyribonuclease medical

"highlighting the therapeutic potential of Deoxyribonuclease (DNase) -based interventions"

An enzyme that acts like microscopic scissors for DNA, cutting long DNA strands into smaller pieces by breaking the chemical links that hold the backbone together. Investors care because these enzymes are essential tools in laboratory testing, genetic engineering, and some drug formulations: they affect the speed and cost of research, the reliability of diagnostics, and the commercial potential of therapies that rely on controlled DNA removal or modification.

dnase i medical

"evaluating DNase I in combination with standard-of-care and immunotherapy platforms"

DNase I is an enzyme that cuts DNA strands into smaller pieces, like molecular scissors that break long threads into shorter fragments. For investors, DNase I matters because it is used in medical treatments, laboratory tests and manufacturing processes; changes in clinical trial results, regulatory approval, patent control, or production capacity can affect companies’ revenues and costs in biotech, diagnostics and contract manufacturing.

pancreatic ductal adenocarcinoma medical

"Ongoing pancreatic ductal adenocarcinoma (PDAC) study"

A fast-growing cancer that starts in the cells lining the pancreas’ small ducts; it is the most common and aggressive form of pancreatic cancer. It matters to investors because its severity and limited treatment options drive high unmet medical need, large potential markets for effective drugs or diagnostics, and strong sensitivity of company valuations to clinical trial results, regulatory approvals, or changes in treatment guidelines—similar to how fixing a main leak can prevent major damage in a building.

large b-cell lymphoma medical

"Proposed large B-cell lymphoma (LBCL) study in combination with Chimeric Antigen Receptor"

Large B‑cell lymphoma is a type of fast-growing cancer that starts in B cells, a kind of white blood cell that helps the body fight infection. For investors it matters because the condition drives demand for diagnostics, treatments and clinical trials; positive or negative trial results, regulatory decisions or new therapies can quickly change a biotech or drug maker’s revenue prospects, similar to how a breakthrough product can reshape a company’s future.

car t cell therapy medical

"large B-cell lymphoma (LBCL) study in combination with Chimeric Antigen Receptor (CAR) T cell therapy"

A therapy that engineers a patient's own immune cells (T cells) so they can recognize and kill cancer cells, like retraining a guard dog to detect a specific scent. It matters to investors because these treatments can be transformative and command high prices, yet require complex manufacturing and face regulatory, safety and reimbursement risks that can greatly influence a biotech or drugmaker’s valuation and future revenue.

investigational new drug regulatory

"Advanced clinical manufacturing activities for DNase I toward Investigational New Drug (IND) application"

An investigational new drug is a medication that is still being tested in clinical trials to determine if it is safe and effective for treating a specific condition. For investors, it represents a potential breakthrough that could lead to a new treatment and significant financial gains if successful, but also carries risks since it has not yet been approved for widespread use.

translational research medical

"Current focus on mechanism-of-action and translational research studies supported by encouraging CAR-T"

Translational research turns laboratory discoveries into tests, treatments, or medical products for people, acting as the bridge between basic science and practical use. Like converting a prototype into a store-ready product, it shows whether promising biology can become a safe, regulated, and sellable therapy, diagnostic, or device. For investors, clear translational progress reduces technical and regulatory uncertainty, creates milestone-driven value, and signals when commercial returns might be possible.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Encouraging preclinical and translational data supporting DNase-based approaches to target NETs in difficult-to-treat cancers

Strategic focus on investigator-initiated exploratory studies and institutional collaborations

Continued progress toward IND-enabling activities for DNase I program

Ended the year with $7.9 million of cash to fund operations

FRAMINGHAM, MA / ACCESS Newswire / March 13, 2026 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers, today reported its financial results for the year ended December 31, 2025.

Recent Highlights

• Expanded and presented preclinical and translational evidence supporting neutrophil extracellular traps (NETs) as drivers of cancer progression and highlighting the therapeutic potential of Deoxyribonuclease (DNase) -based interventions;

• Progressed investigator-initiated exploratory studies in Israel evaluating DNase I in combination with standard-of-care and immunotherapy platforms, including:

  • Ongoing pancreatic ductal adenocarcinoma (PDAC) study;

  • Proposed large B-cell lymphoma (LBCL) study in combination with Chimeric Antigen Receptor (CAR) T cell therapy;

• Advanced clinical manufacturing activities for DNase I toward Investigational New Drug (IND) application;

• Current focus on mechanism-of-action and translational research studies supported by encouraging CAR-T proof-of-concept studies with Scripps Research; and

• Pursuing strategic alternatives to maximize shareholder value.

"During 2025, we continued to advance our DNase-based technology toward Phase 1 clinical development while making steady progress across scientific, operational and strategic fronts," said James Parslow, Interim Chief Executive Officer and Chief Financial Officer of Xenetic. "We strengthened the evidence linking NETs to cancer progression and the therapeutic promise of DNase-based strategies, advanced multiple investigator-initiated studies and progressed toward IND-enabling activities. We believe these efforts position the Company well as we move through 2026, while remaining disciplined in our use of capital and focused on creating long-term shareholder value."

Xenetic continues to advance its DNase-based technology toward Phase 1 clinical development for the treatment of pancreatic carcinoma and other locally advanced or metastatic solid tumors. During 2025, the Company completed preclinical studies evaluating DNase I in combination with chemotherapy, immunotherapies and CAR-T approaches across both solid and hematologic cancer models. Data generated from these studies are informing ongoing translational work and manufacturing activities as the Company progresses toward U.S. IND submission.

Summary of Financial Results for Fiscal Year 2025
Net loss for the year ended December 31, 2025 was approximately $2.7 million, reflecting investment in the Company's most promising scientific programs. Royalty revenue from the Company's sublicense with Takeda Pharmaceuticals Co. Ltd increased approximately 19% to $3.0 million in the year ended December 31, 2025 from $2.5 million for the year ended December 31, 2024 primarily due to royalty payments received from certain countries. Research and development expenses for the year ended December 31, 2025 decreased by approximately $0.2 million, or 7%, to $3.1 million from $3.3 million in the prior year period. Research and development costs for the year ended December 31, 2024 included a $0.7 million impairment charge that did not reoccur in 2025. This decrease was substantially offset by increased spending in connection with the Company's DNase process development efforts. General and administrative expenses for the year ended December 31, 2025 were $2.7 million, decreasing by approximately $0.7 million, or 20%, compared to the prior year. This decrease was primarily due to certain severance and benefits expensed during the year ended December 31, 2024 in connection with a separation agreement entered into during the second quarter of 2024 with our former Chief Executive Officer.

The Company ended the year with approximately $7.9 million of cash, representing an increase of approximately $1.7 million compared to the prior year-end, primarily due to net proceeds of approximately $4.0 million from an underwritten public offering completed in October 2025.

About Xenetic Biosciences
Xenetic Biosciences, Inc. is a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers. The Company's proprietary DNase technology is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in cancer progression. Xenetic is currently focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and locally advanced or metastatic solid tumors.

For more information, please visit the Company's website at www.xeneticbio.com and connect on X, LinkedIn, and Facebook.

Forward-Looking Statements
This press release contains forward-looking statements that we intend to be subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release other than statements of historical facts may constitute forward-looking statements within the meaning of the federal securities laws. These statements can be identified by words such as "expects," "plans," "projects," "will," "may," "anticipates," "believes," "should," "intends," "estimates," "remain," "focus", "confidence in", "potential", "continues", "warrants", and other words of similar meaning, including, but not limited to, all statements regarding our belief that our efforts position the Company well as we move through 2026, while remaining disciplined in our use of capital and focused on creating long-term shareholder value, expectations regarding data generated informing ongoing translational work and manufacturing activities as the Company progresses toward U.S. IND submission, our focus on advancing innovative immuno-oncology technologies addressing difficult to treat cancers, the DNase platform improving outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in cancer progression, and our focus on advancing our systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and locally advanced or metastatic solid tumors. Any forward-looking statements contained herein are based on current expectations and are subject to a number of risks and uncertainties. Many factors could cause our actual activities, performance, achievements, or results to differ materially from the activities and results anticipated in forward-looking statements. Important factors that could cause actual activities, performance, achievements, or results to differ materially from such plans, estimates or expectations include, among others, (1) unexpected costs, charges or expenses resulting from our manufacturing and collaboration agreements; (2) unexpected costs, charges or expenses resulting from the licensing of the DNase platform; (3) uncertainty of the expected financial performance of the Company following the licensing of the DNase platform; (4) failure to realize the anticipated potential of the DNase or PolyXen technologies; (5) the ability of the Company to obtain funding and implement its business strategy; (6) risks and uncertainties as to the outcome and timing of the strategic review process being conducted by the Board and a special independent committee thereof, including the possibility that the Board may decide not to undertake a strategic alternative following the evaluation process, the Company's inability to consummate any proposed strategic alternative resulting from the review due to, among other things, market, regulatory and other factors, the potential for disruption to our business resulting from the review process, and potential adverse effects on the Company's stock price from the announcement, suspension or consummation of the evaluation process and the results thereof, as well as risks and uncertainties related to the potential impacts of consummation of a strategic transaction on the Company's current business operations, anticipated business strategy and product development plans; and (7) other risk factors as detailed from time to time in the Company's reports filed with the SEC, including its annual report on Form 10-K, periodic quarterly reports on Form 10-Q, current reports on Form 8-K and other documents filed with the SEC. The foregoing list of important factors is not exclusive. In addition, forward-looking statements may also be adversely affected by general market factors, general economic and business conditions, including potential adverse effects of public health issues, and geopolitical events, such as the conflicts in Ukraine and in the Middle East, on economic activity, competitive product development, product availability, federal and state regulations and legislation, the regulatory process for new product candidates and indications, manufacturing issues that may arise, patent positions, litigation, and shareholder activism, among other factors. The forward-looking statements contained in this press release speak only as of the date the statements were made, and the Company does not undertake any obligation to update forward-looking statements, except as required by law.

CONTACT:
JTC Team, LLC
Jenene Thomas
(908) 824-0775
xbio@jtcir.com

SOURCE: Xenetic Biosciences, Inc.

View the original press release on ACCESS Newswire

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What were Xenetic Biosciences (XBIO) full-year 2025 financial results?

Xenetic reported a net loss of $2.7 million for 2025, with royalty revenue of $3.0 million. According to the company, royalty revenue rose ~19% year-over-year, R&D expenses were $3.1 million, and year-end cash totaled approximately $7.9 million.

How much cash did Xenetic Biosciences (XBIO) have at year-end 2025?

Xenetic ended 2025 with approximately $7.9 million in cash, an increase of ~$1.7 million. According to the company, the increase primarily reflected net proceeds of ~ $4.0 million from an October 2025 public offering.

What progress did Xenetic (XBIO) report on its DNase I program in 2025?

Xenetic advanced preclinical and translational work and moved toward IND-enabling activities for DNase I. According to the company, studies included combination work with chemotherapy, immunotherapies and CAR-T, and ongoing investigator-initiated trials in PDAC.

What drove the change in Xenetic's research and development expenses in 2025?

R&D expenses decreased to $3.1 million in 2025, partly due to a prior-year impairment not repeating. According to the company, this decline was substantially offset by increased spending on DNase process development efforts.

What clinical studies involving DNase I did Xenetic (XBIO) support in 2025?

Xenetic supported investigator-initiated exploratory studies including an ongoing PDAC trial and a proposed LBCL study with CAR-T. According to the company, translational work and CAR-T proof-of-concept studies with Scripps Research also informed development plans.